<DOC>
	<DOC>NCT01165502</DOC>
	<brief_summary>The primary objective is to assess the safety and tolerability of the GLP-1 peptide analogue CM3.1-AC100 after repeated subcutaneous (sc) doses.</brief_summary>
	<brief_title>Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Multiple Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Provision of signed and dated informed consent prior to any study specific procedures; Male volunteer aged 18 to 50 years at Screening, both inclusive; Body weight between 60.0 to 100.0 kg (both inclusive) and BMI 19 to 29.9 kg/m2 (both inclusive) Any history or presence of a clinically relevant disease as judged to be relevant by the Investigator: cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, haematological, neurologic, psychiatric, systemic, ocular or infectious disease and any acute infectious disease or signs of acute illness; Blood donation within 3 month before administration of the IP; Presence or history of drug allergy, or allergic disease diagnosed and treated by a physician</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>MAD study CM3.1-AC100</keyword>
	<keyword>Healthy men, age 18 - 50</keyword>
</DOC>